What is Proveca?
Proveca Ltd is a Manchester-based pharmaceutical firm dedicated to developing and commercializing medicines specifically for children. This specialized focus addresses a historically underserved segment within the pharmaceutical industry, where age-appropriate formulations and dosages are crucial. The company's commitment to pediatric health positions it as a key player in improving treatment outcomes for younger patient populations. Its strategic capital injections are geared towards accelerating research and development, enhancing manufacturing capabilities, and broadening market access for its specialized pharmaceutical products.
How much funding has Proveca raised?
Proveca has raised a total of $9.2M across 2 funding rounds:
Private Equity
$4.2M
Private Equity
$5M
Private Equity (2013): $4.2M with participation from Albion Ventures
Private Equity (2017): $5M led by Kreos Capital, Catapult Ventures, and GM&C Life Sciences Fund
Key Investors in Proveca
Albion Ventures
AlbionVC is the technology investment arm of Albion Capital Group LLP, managing approximately £1 billion in venture funds and supporting visionary founders with long-term capital and scale-up expertise. The firm primarily invests in high-growth B2B software and technology-enabled services companies, focusing on early-stage investments from seed to Series B, predominantly in the UK.
Kreos Capital
Kreos Capital Group Ltd is a company that specializes in finance, providing investment services and business management. The company was formed in 1998 and is headquartered in London, United Kingdom.
Catapult Ventures
Catapult Ventures specializes in providing tailored investment solutions to meet the funding needs of entrepreneurs and business owners. The company focuses on unlocking potential and supporting clients in realizing their goals and ambitions.
What's next for Proveca?
With the recent influx of major strategic investment, Proveca is poised for accelerated growth and innovation. The substantial backing suggests a strong market validation of its business model and therapeutic pipeline. Future endeavors will likely concentrate on expanding its product portfolio, potentially through further research, strategic partnerships, or acquisitions. The company's trajectory indicates a move towards solidifying its market leadership in pediatric pharmaceuticals, leveraging this capital to drive significant advancements in child healthcare and establish new benchmarks in the industry.
See full Proveca company page
